world
Brooklyn Bodegas Sell Retatrutide Vials for $95 Without Prescription
A CBS News reporter bought a vial of the experimental drug at Mr. Green on Bedford Avenue without any verification. The same Indr Labs product appeared at a second store two blocks away.
nypost.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A CBS News reporter bought a vial labeled retatrutide for $95 at Mr. Green bodega on Bedford Avenue in Brooklyn on Tuesday afternoon. The purchase required no age verification, medical questionnaire or prescription.
Mr. " That language does not appear on the vial itself. Federal law prohibits commercial sale of experimental drugs to the public except in limited clinical-trial or animal-research circumstances. The certificate of analysis for retatrutide on Indr Labs' website shows a graph that appears to identify the sample as tirzepatide.
Tori Johnson, operations manager of Vanguard Laboratory, stated by email that Vanguard did not issue the certificates and has no client named INDR Labs. Indr Labs subsequently changed its website to require a password to access the lab reports. Classy Bite Deli 2, located barely two blocks from Mr.
Green on Bedford Avenue, displayed the same Indr Labs poster and offered retatrutide for sale. " Jeff Cohen stated that advertising research-grade retatrutide in a retail store was "incredibly aggressive" and "probably the most aggressive form of product placement" he has seen for retatrutide. He added, "Selling research-use peptides is like driving on an interstate...
In clinical trials, retatrutide has shown potential to be more effective than the most potent FDA-approved weight-loss drugs. America's Poison Centers has tracked a sharp rise in reports of toxicities attributed to retatrutide. Last month, CBS News documented that retatrutide was being widely prescribed by licensed medical professionals without regulatory approval.
On the same day that report appeared, a 72-year-old woman contacted the FDA reporting "sever [sic] skin irritation and still seeing doctors" after being prescribed the drug.
